Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Flexion Therapeutics Inc    FLXN

 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
12/05/2017 12/06/2017 12/07/2017 12/08/2017 12/11/2017 Date
25.44(c) 24.94(c) 25.18(c) 25.47(c) 24.91(c) Last
756 041 1 012 156 809 826 1 204 277 924 049 Volume
-1.01% -1.97% +0.96% +1.15% -2.20% Change
More quotes
Financials ($)
Sales 2017 0,60 M
EBIT 2017 -120 M
Net income 2017 -124 M
Finance 2017 304 M
Yield 2017 -
Sales 2018 28,2 M
EBIT 2018 -139 M
Net income 2018 -120 M
Finance 2018 322 M
Yield 2018 -
P/E ratio 2017 -
P/E ratio 2018
EV / Sales2017 1 052x
EV / Sales2018 21,7x
Capitalization 935 M
More Financials
Company
Flexion Therapeutics, Inc. is a pharmaceutical company, which focuses on the development and commercialization of novel, local therapies.The firm specializes in treatment of patients with musculoskeletal conditions including osteoarthritis.It offers products under the Zilretta brand.The company... 
Sector
Biotechnology & Medical Research
Calendar
12/14 | 02:30pmPresentation
More about the company
Surperformance© ratings of Flexion Therapeutics Inc
Trading Rating : Investor Rating :
More Ratings
Latest news on FLEXION THERAPEUTICS INC
11:13a FLEXION THERAPEUTICS : Announces Appointment of Scott Kelley, M.D. as Chief Medi..
12/11 FLEXION THERAPEUTICS : Announces Appointment of Scott Kelley, M.D. as Chief Medi..
12/07 FLEXION THERAPEUTICS : Enrolls First Patient in Phase 2 Pharmacokinetics and Saf..
12/07 Flexion Therapeutics Enrolls First Patient in Phase 2 Pharmacokinetics and Sa..
12/06 FLEXION THERAPEUTICS : to Present at the BMO Capital Markets Prescriptions for S..
12/06 Flexion Therapeutics to Present at the BMO Capital Markets Prescriptions for ..
12/04 FLEXION THERAPEUTICS : Reports Inducement Grants Under NASDAQ Listing Rule 5635(..
12/04 Flexion Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 563..
11/28 Flexion Therapeutics to Present at Evercore ISI 2017 Biopharma Catalyst/Deep ..
11/27 FLEXION THERAPEUTICS INC : Today's Research Reports on Stocks to Watch: Flexion ..
More news
Sector news : Bio Therapeutic Drugs
10:43a M&A dominates Europe share trading as oil leads gains
12/09 Tax-loss selling to pressure 2017's losers in December
11/30 GENMAB : and J&J 'love' partnership as some ponder takeover
11/27 MERCK AND : As Brexit looms, UK pitches new industry plan, wins support from Mer..
11/27 MERCK AND : As Brexit looms, UK pitches new industry plan, wins support from Mer..
More sector news : Bio Therapeutic Drugs
News from SeekingAlpha
11/20 Flexion launches Zilretta in U.S.; shares ahead 2%
11/12 YOUR DAILY PHARMA SCOOP : Neurocrine Has Upside, Dynavax Gets FDA Nod, Sage Soar..
11/06 Flexion Therapeutics' (FLXN) CEO Mike Clayman on Q3 2017 Results - Earnings C..
11/06 Flexion Therapeutics misses by $0.09
10/31 BIOTECH FORUM DAILY DIGEST : Possible Buyout Scenarios For Neos Therapeutics
Chart FLEXION THERAPEUTICS INC
Duration : Period :
Flexion Therapeutics Inc Technical Analysis Chart | FLXN | US33938J1060 | 4-Traders
Technical analysis trends FLEXION THERAPEUTICS INC
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 8
Average target price 38,4 $
Spread / Average Target 54%
EPS Revisions
Managers
NameTitle
Michael D. Clayman President, Chief Executive Officer, CFO & Director
Patrick J. Mahaffy Chairman
Neil Bodick Chief Scientific Officer
Yamo Deniz Chief Medical Officer
Samuel D. Colella Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
FLEXION THERAPEUTICS INC33.91%935
GILEAD SCIENCES1.55%99 094
REGENERON PHARMACEUTICALS1.78%40 969
VERTEX PHARMACEUTICALS88.38%35 831
GENMAB1.79%11 452
BLUEBIRD BIO INC172.12%9 249